- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00339911
Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick
Collection and Distribution of Samples From Healthy Donors for In Vitro Research at NCI-Frederick
Background
-NCI-Frederick scientists performing in vitro studies involving human specimens have a need for a reliable and consistent source of samples which protects the donor from research risks.
Objective
-The purpose of this protocol is to establish a centralized repository for the collection and distribution of samples (either blood, buccal mucosal cells, semen, urine, or nail clippings) from paid, healthy volunteer donors for in vitro research conducted by NIH investigators located at NCI-Frederick and Ft. Detrick. Research will include, but are not limited to, genotype analysis, immune function studies, drug screening, vaccine development, method development, quality control testing of reagents, and propagation of infectious agents, including HIV.
Eligibility:
Healthy NCI-Frederick employees and other NIH staff located at Ft. Detrick will be recruited. Potential donors will be excluded if screening indicates exposure to HIV, HTLV, Hepatitis C or Hepatitis B virus infection.
Study Design:
Investigators requesting to participate to the Research Donor Program (RDP) by receiving samples for research use will be required to submit a written memo of request, briefly describing the nature of the research and providing assurance that samples provided through this protocol will be used solely for in vitro research.
These Investigators will receive samples that will be either anonymous or coded, depending on the specific need.
Codes will be securely maintained and under no circumstances will donor identity be released to Investigators.
Donors will receive financial compensation for their time, discomfort and inconvenience according to an established schedule; compensation for blood donation is based on the volume donated.
Study Overview
Status
Conditions
Detailed Description
Background
-NCI-Frederick scientists performing in vitro studies involving human specimens have a need for a reliable and consistent source of samples which protects the donor from research risks.
Objective
-The purpose of this protocol is to establish a centralized repository for the collection and distribution of samples (either blood, buccal mucosal cells, semen, urine, or nail clippings) from paid, healthy volunteer donors for in vitro research conducted by NIH investigators located at NCI-Frederick and Ft. Detrick. Research will include, but are not limited to, genotype analysis, immune function studies, drug screening, vaccine development, method development, quality control testing of reagents, and propagation of infectious agents, including HIV.
Eligibility:
Healthy NCI-Frederick employees and other NIH staff located at Ft. Detrick will be recruited. Potential donors will be excluded if screening indicates exposure to HIV, HTLV, Hepatitis C or Hepatitis B virus infection.
Study Design:
Investigators requesting to participate to the Research Donor Program (RDP) by receiving samples for research use will be required to submit a written memo of request, briefly describing the nature of the research and providing assurance that samples provided through this protocol will be used solely for in vitro research.
These Investigators will receive samples that will be either anonymous or coded, depending on the specific need.
Codes will be securely maintained and under no circumstances will donor identity be released to Investigators.
Donors will receive financial compensation for their time, discomfort and inconvenience according to an established schedule; compensation for blood donation is based on the volume donated.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Maryland
-
Frederick, Maryland, United States, 21702-1201
- NCI Frederick Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- INCLUSION CRITERIA:
Individuals must meet the following eligibility criteria to be entered into the RDP donor pool, as follows:
- Age 18 or older.
- Weight of 110 lb or greater.
- All subjects must have the ability and agree to participate fully and comply with the procedures of the protocol and provide informed consent.
- Registration for participation in semen donation is limited to males currently enrolled in the donor pool.
- Subjects must be NCI Frederick Employees
EXCLUSION CRITERIA:
Individuals with any of the following will be excluded from the donor pool:
- History of chronic illness that might increase the risks associated with phlebotomy, including but not limited to heart, lung, or kidney disease
- Current acute illness.
- History of clotting disorders.
- Current medications which might increase the risk associated with phlebotomy.
- History of syncope or other difficulty with venipuncture.
Anemia, as determined by hematocrit or hemoglobin.
Hemotacrit acceptable range for males: 40-51 percent.
Hemotacrit acceptable range for females: 34-46 percent.
Hemoglobin acceptable range for males: 12.5-17.0 g/dl
Hemoglobin acceptable range for females: 11.5-15.2 g/dl
- Positive blood test for exposure to HIV-1, HIV-2, HTLV-1, HTLV-2, or HCV or for HBV surface antigens.
- Individuals whose activities or conditions place them at high risk of HIV infection are asked not to donate.
- Males who qualify for participation in the donor pool will be excluded from participation in semen donation if they have knowingly had any injury, infection, or treatment performed that renders them incapable of producing sperm.
- Pregnancy: Pregnant women will not be allowed to enroll in this study because there is no benefit.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
1/ single cohort
Healthy NCI Frederick Cancer Research and Development Center employees
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Establish a centralized repository for the collection and distribution ofsamples
Time Frame: Ongoing
|
Collection of biospecimens
|
Ongoing
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Janelle Cortner, Ph.D., National Cancer Institute (NCI)
Publications and helpful links
General Publications
- Merz JF, Sankar P, Taube SE, Livolsi V. Use of human tissues in research: clarifying clinician and researcher roles and information flows. J Investig Med. 1997 Jun;45(5):252-7. No abstract available.
- McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998 Oct;38(10):938-43. doi: 10.1046/j.1537-2995.1998.381098440858.x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 999999046
- OH99-C-N046
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Donors
-
Terumo BCTCompletedHealthy Apheresis Donors | Mononuclear (MNC) Cell DonorsUnited States
-
Gangnam Severance HospitalActive, not recruitingHealthy Donors for Liver TransplantationKorea, Republic of
-
National Institutes of Health Clinical Center (CC)CompletedHealthy Apheresis DonorsUnited States
-
Heinrich-Heine University, DuesseldorfChugai Pharma USA; Terumo BCTCompletedHealthy Allogeneic Donors | Granulocyte Colony-stimulating Factor (G-CSF) MobilizedGermany
-
National Institute of Allergy and Infectious Diseases...CompletedLiving Donors | Tissue Donors
-
Cliniques universitaires Saint-Luc- Université...CompletedHealthy Donors | Pediatric Liver Transplanted Recipients
-
Samsung Medical CenterCompletedHealthy Donors for Liver TransplantationKorea, Republic of
-
BioCytics, Inc.RecruitingSolid Tumor, Adult | Healthy Donors | COVID-19 DonorsUnited States
-
Ohio UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Blood CenterCompleted
-
Universidad Peruana Cayetano HerediaCompleted